US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

September 15, 2017: By Jon Swedien

legal issuesThe US Patent Trial and Appeal Board has denied Coherus BioSciences’ four petitions seeking invalidation of a Humira patent held by Chicago-based AbbVie, Coherus announced Sept. 7.

Humira (adalimumab) posted sales of $16 billion in 2016, accounting for most of AbbVie’s revenues.

The anti-inflammatory drug is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and several other diseases and medical conditions.

In June 2016, the FDA approved Humira as a treatment for noninfectious intermediate and posterior uveitis and panuveitis.

The drug is protected by several patents that run through 2022.

Coherus prevailed in May in a petition against a different Humira patent.

The Redwood City, California, company has created a biosimilar version of Humira, CHS-1420.

Coherus planned to file for US approval of its biosimilar in the first half of 2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility